Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy
JAMA · 2024
DOI: 10.1001/jama.2023.26113 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Emily Harris. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, CRISPR-Cas Systems, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref).
Abstract (Originalsprache)
The US Food and Drug Administration (FDA) recently greenlit 2 cell-based gene treatments for sickle cell anemia, including the first therapy involving the genome editing technology known as CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats–CRISPER-associated protein 9).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Harris, E. (2024). Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy. JAMA. https://doi.org/10.1001/jama.2023.26113
Vancouver
Harris E. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy. JAMA. 2024. doi:10.1001/jama.2023.26113
BibTeX
@article{Harris2024,
author = {Harris, Emily},
title = {Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2023.26113}
}
EUVIMED